2016 年第 2 期 第 14 卷

替吉奥联合奥沙利铂化疗方案治疗高龄晚期胃癌的临床研究

作者：

单位：

关键词：奥沙利铂替吉奥化疗高龄晚期胃癌临床疗效

• 摘要：
• 【摘要】目的：研究SOX（S-1 and Oxaliplatin）化疗方案治疗高龄晚期胃癌的临床的临床疗效；方法：选择2012年1月～2014年12月在我院收治且行化疗的高龄晚期胃癌患者126例，将所有高龄晚期胃癌患者按照随机数字表法分为SOX组与对照组，SOX组63例，对照组63例，两组患者一般资料比较无统计学差异（p＞0.05）。对照组给予顺铂联合替吉奥方案化疗，SOX组给予奥沙利铂联合替吉奥方案（SOX化疗方案）化疗，检测两组化疗前、两周期化疗后免疫指标百分率、毒副作用、近期疗效以及患者受益情况；结果：两组组化疗后CD4+、CD4+/CD8+水平显著高于化疗前，p＜0.05。化疗后SOX组CD4+、CD4+/CD8+水平高于对照组，p＜0.05。两组客观有效率、受益率无统计学意义，p＞0.05。SOX组恶心呕吐发生率显著低于对照组，p＜0.05；结论：SOX化疗方案治疗高龄晚期胃癌疗效显著，毒副作用小，值得应用于临床。
• Objective: To study the clinical effect of clinical SOX chemotherapy in the treatment of old patients with advanced gastric cancer; methods: 2014 January to 2014 December in our hospital and received chemotherapy of elderly patients with advanced gastric cancer patients with 126 cases, all the old patients with advanced gastric cancer were randomly divided into SOX group and control group, 63 in SOX group cases, 63 cases in the control group, no significant differences between the two groups of patients with general information (P>0.05). The control group was given cisplatin combined with gimeracil chemotherapy, group SOX were given oxaliplatin combined with gimeracil chemotherapy (SOX regimen), two groups were detected before chemotherapy, after two cycles of chemotherapy, immune index of side effects, efficacy and patient benefit; results: CD4+, CD4+/CD8+ levels of two groups were significantly higher than before chemotherapy and after chemotherapy, P is less than 0.05. In group SOX, CD4+, CD4+/CD8+ levels after chemotherapy was higher than that in the control group, P < 0.05. The two objective response rate, the benefit rate was not statistically significant, P > 0.05. Nausea and vomiting in group SOX was significantly lower than that in the control group, P < 0.05; conclusion: SOX chemotherapy is effective in treating elderly patients with advanced gastric cancer, small toxic side effect, is worthy of clinical application.